2025 Q1 update Strong revenue growth yoy 45% exceding expectations. Strong EPS of 178%, however easy comps should be noted.Read more
Key Takeaways Enlarged European market reach and a deep pipeline of generics underpin prospects for robust, sustained revenue and margin growth. Operational efficiencies, disciplined acquisitions, and targeted R&D boost earnings quality and position EQL Pharma for enhanced resilience and market value.Read more
EQL Pharma AB (publ) engages in the development, marketing, and sale of generic medicines to pharmacies and hospitals in Sweden, Denmark, Norway, Finland, and the rest of Europe. It offers injection products for inpatient care and formulations for outpatient care. EQL Pharma AB (publ) was incorporated in 2006 and is based in Lund, Sweden.
